ScreenerHero

GNLX Genelux Corporation

NAS · US · Healthcare · Biotechnology · genelux.com
2.520USD-0.79%Mkt Cap: 114.02M $P/E: —

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap114.02M USD
Enterprise Value97.57M USD
Revenue (TTM)8.00K USD
Gross Profit8.00K USD
Net Income (TTM)-32.15M USD
Revenue/Share0.00 USD
Last Price2.520 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees25
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.38
PEG—
EV/EBITDA-2.69
EV/Revenue12196.56
P/S14365.39
P/B7.04
EPS (TTM)-0.83
EPS (Forward)-0.75
52W Range
2.2904% of range8.535
52W High8.535 USD
52W Low2.290 USD
Profitability
Gross Margin100.00%
Oper. Margin-455275.00%
EBITDA Margin0.00%
Profit Margin-401812.50%
ROE-278.46%
ROA-168.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-25.27M USD
CapEx (TTM)1.10M USD
FCF Margin-190659.38%
FCF Yield-13.38%
Net Debt-16.25M USD
Net Debt/EBITDA0.45
Balance Sheet
Debt/Equity0.15
Current Ratio2.39
Quick Ratio2.33
Book Value/Sh0.36 USD
Cash/Share0.42 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)18.83 USD
Upside (mean)+647.4%
Target Range12.00 USD – 31.00 USD
12.00+647.4% to mean31.00
# Analysts6
Ownership
Shares Out.45.25M
Float36.44M
Insiders12.87%
Institutions31.01%
Short Interest
Short Ratio12.6d
Short % Float9.32%
Short % Out.9.05%
Shares Short4.10M
Short (prev mo.)3.52M
Technical
SMA 502.637 (-4.4%)
SMA 2002.833 (-11.0%)
Beta0.58
S&P 52W Chg16.45%
Avg Vol (30d)256.70K
Avg Vol (10d)187.10K
Technical Indicators
RSI (14)46.6
MACD-0.0303
MACD Signal-0.0461
MACD Hist.+0.0158
BB Upper2.611 USD
BB Middle2.518 USD
BB Lower2.425 USD
BB Width7.39%
ATR (14)0.1318 USD
Vol Ratio (20d)2.44x